Skip to content
Study details
Enrolling now

A Research Trial on Weekly Insulin vs. Daily Insulin

Novo Nordisk A/S
NCT IDNCT07076199ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

877

Study length

about 1.4 years

Ages

18+

Locations

103 sites in AL, CA, CO +28

About this study

Researchers are testing whether a weekly insulin, called insulin icodec, helps reduce blood sugar compared to daily insulin glargine, both in combination with insulin aspart, in adults with type 1 diabetes. The trial will last for about 8.5 months and involve approximately 877 participants.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Receive Insulin aspart
  • 2.Receive Insulin glargine
  • 3.Receive Insulin icodec
PhasePhase 3
DrugInsulin aspart
Routeinjection
Primary goalChange in glycosylated haemoglobin (HbA1c)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

insulin aspart, insulin glargine (Long-acting insulin; helps glucose uptake into cells)

Drug routes

injection

Endpoints

Primary: Change in glycosylated haemoglobin (HbA1c)

Secondary: Change in body weight

Body systems

Endocrinology